Compare TYRA & DCO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | TYRA | DCO |
|---|---|---|
| Founded | 2018 | 1849 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Military/Government/Technical |
| Sector | Health Care | Industrials |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.0B | 1.9B |
| IPO Year | 2021 | 1995 |
| Metric | TYRA | DCO |
|---|---|---|
| Price | $28.28 | $162.51 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 11 | 5 |
| Target Price | $47.50 | ★ $153.60 |
| AVG Volume (30 Days) | ★ 807.7K | 178.7K |
| Earning Date | 05-06-2026 | 05-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | N/A | ★ 0.64 |
| Revenue | N/A | ★ $824,730,000.00 |
| Revenue This Year | N/A | $7.40 |
| Revenue Next Year | N/A | $8.59 |
| P/E Ratio | ★ N/A | $256.73 |
| Revenue Growth | N/A | ★ 4.85 |
| 52 Week Low | $8.98 | $80.12 |
| 52 Week High | $40.65 | $168.74 |
| Indicator | TYRA | DCO |
|---|---|---|
| Relative Strength Index (RSI) | 42.75 | 66.02 |
| Support Level | $27.40 | $135.11 |
| Resistance Level | $31.57 | N/A |
| Average True Range (ATR) | 1.98 | 6.19 |
| MACD | 0.26 | 0.93 |
| Stochastic Oscillator | 42.12 | 80.11 |
Tyra Biosciences Inc is a clinical-stage biotechnology company focused on developing next-generation precision medicines for large opportunities in targeted oncology and genetically defined conditions, harnessing the power of Fibroblast Growth Factor Receptor (FGFR) biology. The company's in-house precision medicine platform, SNAP, enables rapid and precise drug design through iterative molecular SNAPshots that help to design and predict which product candidates may demonstrate the highest potency, selectivity, and tolerability in the clinic. The various drug candidates in the company's product pipeline are FGFR3, FGFR4/3, and FGFR1/2/3: three clinical-stage, novel small molecules designed to overcome the toxicity and resistance liabilities of first-generation pan-FGFR inhibitors.
Ducommun Inc provides engineering & manufacturing services for high-performance products & high-cost-of failure applications used in the aerospace and defense, industrial, medical & other industries. The company's reportable segments are Structural Systems & Electronic Systems. Structural Systems designs, engineers and manufactures various sizes of complex contoured aerostructure components and assemblies and supplies composite and metal bonded structures and assemblies. Electronic Systems designs, engineers and manufactures high-reliability electronic and electromechanical products used in technology-driven markets including A&D and Industrial end-use markets. It generates maximum of its revenue from the Electronic Systems.